Home/Pipeline/YP-10

YP-10

Presbyopia

NDA FiledUnder FDA Review (PDUFA date set)N/A

Key Facts

Indication

Presbyopia

Phase

NDA Filed

Status

Under FDA Review (PDUFA date set)

Company

Viatris

About Viatris

Viatris is a mission-driven global healthcare company formed in 2020 to empower people worldwide to live healthier lives through expanded access to medicines. Its strategy is built on four complementary pillars—generics, complex generics, biosimilars, and established brands—enabling it to deliver a broad portfolio across therapeutic areas and economic spectrums. The company has established itself as a leader in biosimilars and complex generics, managing a significant pipeline of 247 candidates while executing a strategic transformation to optimize its portfolio and drive sustainable growth through 2030.

View full company profile

Therapeutic Areas

Cardiology Dermatology Immunology Infectious Diseases Central Nervous System Disorders Oncology Respiratory

Other Presbyopia Drugs

Drug	Company	Phase	Status
Presbyopia Treatment	Viatris (2)	Filed/Under Review	Active
Flexivue Microlens	Presbia	Approved	Active
LB-01	Lento Bio	Discovery/IND-Enabling	Active
LB-02	Lento Bio	Discovery	Active
Presbyopia-Correcting Contact Lenses	Clerio Vision	Development	Active
Intra-corneal Implant	MAG Optics	Pre-clinical	Active
Novel Presbyopia & Refractive Therapies	Bausch + Lomb	Clinical Development	Active
NVK029	Vyluma	Phase 2	Active
ArtiPlus	Ophtec	Clinical Trials	Active
BRIMOCHOL™ PF	Tenpoint Therapeutics	NDA Submitted	Active
DE-128A	Santen Pharmaceutical	Phase 2	Active
VIZZ™ (aceclidine ophthalmic solution) 1.44%	LENZ Therapeutics	Approved	Commercial Launch